Why the study?
The association between major bleeding and the concurrent use of potential pharmacokinetic or pharmacodynamic interacting drugs among direct oral anticoagulant users required assessment.
Does concurrent use of interacting drugs increase the risk of major bleeding in patients taking DOACs?
Population
393 cases with major bleeding and 1494 matched controls from 23 492 new DOAC users in the UK
Comparison
Concurrent use of pharmacokinetic or pharmacodynamic interacting drugs vs DOACs alone
Design
Population-based nested case-control study
Authors
Loading...
May support avoiding antiplatelet or SSRI co-prescription with DOACs; hypothesis-generating and requires prospective confirmation.
Does concurrent use of interacting drugs increase the risk of major bleeding in patients taking DOACs?
Concurrent use of antiplatelet drugs or SSRIs with DOACs significantly increases the risk of major bleeding, whereas pharmacokinetic interacting drugs do not appear to increase this risk.
Zhang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: